Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Wegovy does not directly interact with levothyroxine, but it may slow gastric emptying, potentially affecting absorption
Receptor-target and efficacy comparison: GLP-1 class agents | Agent | GLP-1 | GIP | Glucagon | Approval | Best trial weight loss | |---|---|---|---|---|---| | Liraglutide (Saxenda) | Yes | No | No | FDA-approved | 8.0% at 56 weeks (SCALE) | | Dulaglutide (Trulicity) | Yes | No | No | T2D only | 3.0 kg mean at 52 weeks | | Semaglutide (Wegovy) | Yes | No | No | FDA-approved | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | Yes | Yes | No | FDA-approved | 20.9% at 72 weeks (SURMOUNT-1) | | Retatrutide | Yes | Yes | Yes | Investigational | 24.2% at 48 weeks (Phase 2) | Liraglutide and Dulaglutide: Where They Fit Now Liraglutide (Saxenda, 3 mg once daily subcutaneous) was the first GLP-1 agonist approved specifically for obesity in the United States
Why and when semaglutide is compounded According to the FDA, compounded drugs are made by licensed pharmacists (or under the supervision of pharmacists in outsourcing facilities) who combine, mix, or alter ingredients of a drug
Semaglutide is designed to be released into the subcutaneous fat layer so it can be absorbed gradually
Ro offers branded and compounded options
